8-K: Outset Medical Reports Q2 2026 Results, HCA Deal Signed

Outset Medical announced its second quarter 2026 financial results, reporting a slight 1% year-over-year revenue increase to $31.6 million, alongside a significant expansion in gross margin to 42% and a new three-year, $40 million agreement with HCA Healthcare.

Summary

• Total revenue for the second quarter of 2026 was $31.6 million, a 1% increase from $31.4 million in the prior-year period, but a 14% increase sequentially.
• Recurring revenue, primarily from Tablo consumables and services, was $22.1 million, slightly down from $22.5 million in Q2 2025.
• Gross margin improved significantly to 42.0% from 37.8% in the prior-year period, driven by strong performance in service and other revenue.
• Net cash used in operations for the quarter was $9.5 million, contributing to a total cash, cash equivalents, and restricted cash position of $151 million as of June 30, 2026.
• The company signed a three-year, $40 million agreement with HCA Healthcare to refresh its Tablo system fleet.
• Full-year 2026 revenue guidance remains between $125 million and $130 million, representing a 5% to 9% increase over 2025.
• Non-GAAP gross margin is expected to be in the low-to-mid 40% range for the full year.
• Net loss for the quarter was $18.0 million, compared to $18.5 million in the prior-year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report. While revenue growth is minimal year-over-year, sequential growth and significant gross margin expansion are positive indicators. The HCA Healthcare deal provides future revenue visibility, but the continued net loss and cash burn warrant attention.

Positives

• Gross margin expanded significantly to 42.0% (up from 37.8% in Q2 2025), indicating improved operational efficiency and pricing power.
• Service and other revenue increased by 17% year-over-year to $9.7 million, and its gross margin improved to 32.6% from 6.9% in Q2 2025.
• Secured a significant three-year, $40 million agreement with HCA Healthcare for Tablo system refreshes, enhancing backlog visibility.
• Completed the highest number of new site installations in several years during the quarter.
• Sequential revenue growth of 14% indicates positive momentum.
• Reiterated full-year 2026 revenue guidance of $125 million to $130 million.
• Non-GAAP net loss of $14.7 million was relatively consistent with the prior-year period, despite revenue challenges.

Negatives

• Year-over-year total revenue growth was minimal at 1% ($31.6 million vs. $31.4 million).
• Product revenue decreased by 5% year-over-year to $21.9 million.
• Recurring revenue from consumables and services was slightly down year-over-year ($22.1 million vs. $22.5 million).
• Product gross margin decreased to 46.1% from 48.9% year-over-year.
• The company continues to incur significant net losses ($18.0 million in Q2 2026) and uses cash in operations ($9.5 million in Q2 2026).

Risks

• Factors that could cause actual results or other events to differ materially from forward-looking statements can be found in the Risk Factors section of the Company's public filings with the SEC.
• Potential impact of macroeconomic factors, including changes in tariff or trade laws and policies, on the Company, its customers, and suppliers.
• Ability to respond to and resolve any reports, observations, or other actions by the Food and Drug Administration or other regulators in a timely and effective manner.

Future Outlook

Outset Medical reiterated its 2026 revenue guidance of $125 million to $130 million, representing a 5% to 9% increase over 2025. The company continues to expect non-GAAP gross margin to range between the low-40% to mid-40% for the full year. Management is focused on accelerating adoption, driving long-term growth, and advancing toward profitability.

Management Comments

• "Second quarter results reflect continued progress in strengthening the foundation of our business while positioning Outset for the next phase of growth," said Leslie Trigg, Chair and Chief Executive Officer.
• "During the quarter, we completed our highest number of successful new site installations in several years."
• "We also signed our first refresh agreement, which enhances backlog visibility and marks an important milestone as we begin to capitalize on a significant refresh opportunity."
• "By reshaping how dialysis care is delivered across a large market that needs better solutions, Outset is well positioned to accelerate adoption, drive long-term growth and advance toward profitability."

Industry Context

StockSavvy.ai notes that Outset Medical operates in the dialysis market, a segment facing increasing demand due to an aging population and rising rates of kidney disease. The company's Tablo system aims to disrupt traditional dialysis delivery by offering a more integrated, potentially lower-cost, and flexible solution for both hospital and home settings. The significant gross margin improvement suggests progress in scaling operations and managing costs, which is crucial for medical technology companies aiming for profitability.

Comparison to Industry Standards

• The reported gross margin of 42.0% is an improvement but may still be lower than established players in the broader medical device sector, depending on their product mix and scale.
• The year-over-year revenue growth of 1% is modest and lags behind the typical growth rates seen in rapidly expanding medical technology sub-sectors.
• The HCA Healthcare deal, a major health system, is a positive indicator of market acceptance, comparable to large-scale adoption agreements seen with other innovative medical equipment providers.
• The net loss per share of $0.97 for the quarter indicates ongoing investment in growth and operations, a common characteristic of companies in the scaling phase within the healthcare industry.

Legal Proceedings

• Non-ordinary course litigation charges related to stockholder class action and related derivative lawsuits were incurred.

Stakeholder Impact

• Shareholders: The modest revenue growth and continued net loss may temper short-term investor enthusiasm, while the significant gross margin improvement and HCA deal offer long-term potential.
• Customers (Healthcare Facilities): The HCA Healthcare agreement suggests increased availability and potential refresh of Tablo systems, benefiting large health systems.
• Employees: Continued investment in growth and operational improvements may lead to future expansion opportunities, but ongoing losses could imply cost management pressures.
• Suppliers: Increased installation and refresh activity could lead to higher demand for consumables and services.

Next Steps

• Continue to execute on initiatives to accelerate adoption and drive long-term growth.
• Advance toward profitability.
• Capitalize on the significant refresh opportunity for Tablo systems.
• Continue to expand the Tablo system's presence across healthcare facilities and home settings.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' rating. While the significant improvement in gross margins and the substantial HCA Healthcare agreement are strong positives, the minimal year-over-year revenue growth and continued net loss indicate that the company is still in a turnaround or growth phase that requires further execution. Investors should monitor the company's ability to translate sequential revenue growth into sustained year-over-year increases and progress towards profitability.

Keywords

dialysis, medical technology, Tablo Hemodialysis System, revenue, gross margin, HCA Healthcare, healthcare facilities, kidney care